Get Access
TreelipClinical Program Risk Radar
Oncology Phase 2Methodology
NCT05722977

Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

Public trial-level signal summary for this oncology Phase 2 record.

Back to reportOpen ClinicalTrials.gov
Record overview

Status and phase

Status: NOT_YET_RECRUITING

Phase: PHASE2

Sponsor: Peking Union Medical College Hospital

Condition: Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: stale_update_signal | long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: None

Stopped reason

Context when available

No stop reason available in the current public record.